Evonik's 40% Earnings Leap Meets a Divided Analyst Reception

Evonik delivered a sharp improvement in profitability in the third quarter of 2026, but the market's response was anything but uniform. Adjusted EBITDA climbed 40% year on year to EUR 629 million, comfortably outpacing revenue growth of 13% to EUR 3,825 million. Yet the two analyst houses that moved on the numbers pointed in opposite directions.

DZ Bank downgraded the stock from "Buy" to "Hold" yesterday, though it left its fair value estimate untouched at EUR 22. Jefferies, by contrast, reaffirmed its "Buy" rating with a price target of EUR 20 — below the pre-market price of EUR 20.94. The result is an unusual pairing: the more cautious house carries the higher valuation mark, while the bull's target sits beneath the current quote. Investors reading either call in isolation would miss that nuance.

Guidance Points to the Upper Half

On the corporate side, Evonik said it expects full-year adjusted EBITDA to land in the upper half of its guidance range of EUR 2.0 billion to EUR 2.2 billion. That remains a forecast rather than a booked result, but it sharpens the outlook within the existing framework and complements the picture painted by the completed quarter.

The earnings release was not the only item on yesterday's agenda. Evonik also confirmed the completion of a new specialty silicones plant and a tank farm at its Essen site, a project worth roughly EUR 52 million. Essen ranks as a central hub for the group's silicone production, and the added capacity is designed to cut transport volumes within the international production network and reduce exposure to bottlenecks.

The specialty silicones themselves feed into a broad spread of end markets — insulation materials, mattresses and car seats on one side; adhesives, paints, coatings and cosmetics on the other. The investment therefore touches multiple demand channels rather than a single outlet.

Returns Are the Real Yardstick

Whether the project pays off depends on whether the intended operational gains actually materialise on the shop floor. The headline investment sum says nothing about its eventual contribution to earnings; the benefit is meant to flow from smoother production and logistics.

That matters because the Essen expansion sits alongside a wider restructuring. According to Börsen-Zeitung, Evonik expects to find a buyer for Oxeno in the coming months, with preparations for the sale of Synect running in parallel. Site investment and planned divestments are thus separate building blocks of the same corporate story.

Evonik has set itself a return on capital employed target of 11% by 2029, against a RoCE of 6.1% in 2025 — a gap that demands substantial improvement. Growth alone will not close it; how profitably the company deploys its capital belongs in any assessment of the standalone strategy.

Running in tandem with the expansion is a planned reduction of 3,200 positions worldwide by 2029. The Essen build-out is not a counterweight to the cost programme — the two proceed side by side, investment at a key production site and savings across the group.

Independence Reaffirmed

Interim chief executive Claus Rettig restated the company's claim to independence yesterday. Evonik, by its own account, is not conducting takeover negotiations with BASF, though it remains open to a confidential exchange of information that is purely informational in nature.

The new silicone plant gives that ambition a more tangible operational footing. What it does not do is prove that Evonik can hit its return targets — that will require site investments, portfolio changes and cost savings to pull in the same direction. For shareholders, the takeaway is that strong operating news and the appeal of the equity are two separate questions, and the split analyst verdict shows just how separate they can be.